Pleuromutilins

Discovered in 1950, pleuromutilins have the potential to be developed as a new class of antibiotics for systemic administration in humans.

To Learn more about findings to date of the mechanism of action of pleuromutilins, click here to play video

Pleuromutlins are an area of investigational research for Nabriva

In recent years, the effectiveness of many antibiotics has declined due to growing antibiotic resistance and cross-resistance (when bacterial strains become resistant to multiple classes of antibiotics). As a result, health-care providers have fewer options when treating serious infections. In 2010, the World Health Organization (WHO) stated that antibiotic resistance is one of the three greatest threats to human health.

Pleuromutilins inhibit bacterial growth by binding to a specific site on the bacterial ribosome that is responsible for bacterial protein synthesis. No pleuromutilin being developed by Nabriva has been approved by the FDA for human use.

.

.

.

.

.

.